In this episode, Dr. Kristen Marrone and nurse practitioner Beth Sandy discuss the mechanism and clinical evidence supporting TROP2-directed ADCs, emerging agents and combinations, and ongoing biomarker development to optimize patient selection.

Visit TROP2 ADCs in NSCLC: Mechanisms and ManTROP2 ADCs in NSCLC: Mechanisms and Managementagement to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

In this episode, Dr. Kristen Marrone and nurse practitioner Beth Sandy discuss strategies for preventing the key adverse effects associated with datopotamab deruxtecan (Dato-DXd), including stomatitis, ocular toxicities, and drug-induced interstitial lung disease/pneumonitis.

Visit Managing Toxicities With TROP2-Targeting ADCs for NSCLC to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

In this podcast episode, Andrew Kuykendall, MD, and Sangeetha Venugopal, MD, MS they review the clinical trial and real-world evidence on the efficacy and safety of currently available therapies for patients with lower-risk myelodysplastic syndrome (LR-MDS)-associated anemia. Their thought-provoking discussion will give an overview of the pertinent publications while highlighting the clinical implications of this data, in practice.

Visit https://suitehome.atpointofcare.com/library/2729.02/page/0

to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

In this podcast episode, Andrew Kuykendall, MD, and Sangeetha Venugopal, MD, MS explore dose escalation strategies for the erythroid maturation agent (EMA), luspatercept, in patients with lower-risk myelodysplastic syndrome (LR-MDS). Their engaging discussion will give an overview of the pertinent clinical trial efficacy and safety data and recent changes to the prescribing information, as well as delving into how they both apply this information in their clinical practices.

Visit https://suitehome.atpointofcare.com/library/2729.01/page/0

to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn

In this episode, our expert faculty, medical oncologist Dr. Heather Wakelee, and pathologist Dr. Anil Parwani, explore targeted antibody-drug conjugates (ADCs) in the management of non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGAs). Discussion will include why trophoblast cell surface antigen 2 (TROP2) is a promising target in NSCLC, quantitative continuous scoring (QCS) as a predictive biomarker, current efficacy and safety data from clinical trials, and best practices for monitoring and mitigating ADC-associated adverse events (AEs).

Visit https://suitehome.atpointofcare.com/library/2720.03/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

In this episode, medical oncologist Dr. Charu Aggarwal and nurse practitioner Beth Sandy explore human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugates (ADCs) in the management of advanced non-small cell lung cancer. Their engaging discussion will include topics such as HER2 biomarker testing, current efficacy and safety data from clinical trials, and best practices for monitoring and mitigating ADC-associated toxicities.

Visit https://suitehome.atpointofcare.com/library/2720.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

In this episode, Dr. Charu Aggarwal and Dr. Heather Wakelee explore targeted antibody-drug conjugates (ADCs) in the management of EGFR-mutated NSCLC. Their discussion will include: 1) why trophoblast cell surface antigen 2 (TROP2) is a promising target in NSCLC; 2) quantitative continuous scoring (QCS) as a predictive biomarker; 3) current efficacy and safety data from clinical trials; and 4) best practices for monitoring and mitigating ADC-associated toxicities.

Visit https://suitehome.atpointofcare.com/library/2720.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

In this episode, Rewriting the ET Playbook, Dr. Douglas Tremblay and Dr. Ruben Mesa review the current therapeutic options for treating essential thrombocythemia, and they review therapies on the horizon that are currently in late-stage clinical trials. What do clinicians need to know for managing this blood disorder?

Visit https://suiteweb.atpointofcare.com/#library/mpn/2718.03/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.